U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H14N2O6S3.2Na
Molecular Weight 448.445
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFOXONE SODIUM

SMILES

[Na+].[Na+].[O-]S(=O)CNC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(NCS([O-])=O)C=C2

InChI

InChIKey=AZBNFLZFSZDPQF-UHFFFAOYSA-L
InChI=1S/C14H16N2O6S3.2Na/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20;;/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20);;/q;2*+1/p-2

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C14H14N2O6S3
Molecular Weight 402.466
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Sulfoxone is a water-soluble sulfone and is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. Sulfoxone under the brand name Diasone was used as an antileprosy drug, for treatment of dermatitis herpetiformis, and to treat pulmonary tuberculosis. Presently, usage of diasone has been discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DIASONE SODIUM

Approved Use

Unknown

Launch Date

5.11401591E11
Primary
DIASONE SODIUM

Approved Use

Unknown

Launch Date

5.11401591E11
Primary
DIASONE SODIUM

Approved Use

Unknown

Launch Date

5.11401591E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
600 ng/mL
330 mg single, oral
dose: 330 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DAPSONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
Other AEs: Nausea, Weakness...
Other AEs:
Nausea
Weakness
Sources:
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
Other AEs: Malaise...
1.2 g 1 times / day multiple, oral
Dose: 1.2 g, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 g, 1 times / day
Sources:
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
Disc. AE: Hemolytic anemia, Methemoglobinemia...
AEs leading to
discontinuation/dose reduction:
Hemolytic anemia
Methemoglobinemia
Sources:
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
unhealthy, 52 years
n = 1
Health Status: unhealthy
Condition: leprosy
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Erythema facial, Erythema...
AEs leading to
discontinuation/dose reduction:
Erythema facial
Erythema
Furunculosis
Sources:
AEs

AEs

AESignificanceDosePopulation
Nausea
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
Weakness
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
Malaise
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
Hemolytic anemia Disc. AE
1.2 g 1 times / day multiple, oral
Dose: 1.2 g, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 g, 1 times / day
Sources:
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
Methemoglobinemia Disc. AE
1.2 g 1 times / day multiple, oral
Dose: 1.2 g, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 g, 1 times / day
Sources:
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
Erythema facial Disc. AE
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
unhealthy, 52 years
n = 1
Health Status: unhealthy
Condition: leprosy
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
Erythema Disc. AE
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
unhealthy, 52 years
n = 1
Health Status: unhealthy
Condition: leprosy
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
Furunculosis Disc. AE
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
unhealthy, 52 years
n = 1
Health Status: unhealthy
Condition: leprosy
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
PubMed

PubMed

TitleDatePubMed
p-Sulfooxyphenylpyruvic acid from the red macro alga Ceratodictyon spongiosum and its sponge symbiont Haliclona cymaeformis.
2002 Jun
Asymmetric synthesis of anti-homopropargylic alcohols from aldehydes and chiral sulfonimidoyl substituted bis(allyl)titanium complexes through generation and elimination of novel chiral alkylidenecarbene (dimethylamino)sulfoxonium ylides.
2002 Sep 4
Asymmetric synthesis of unsaturated, fused bicyclic proline analogues through amino alkylation of cyclic bis(allylsulfoximine)titanium complexes and migratory cyclization of delta-amino alkenyl aminosulfoxonium salts.
2003 Oct 29
Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS).
2005
Avoid, attack or do both? Behavioral and physiological adaptations in natural enemies faced with novel hosts.
2005 Nov 4
Diastereomerically and enantiomerically pure 2,3-disubstituted pyrrolidines from 2,3-aziridin-1-ols using a sulfoxonium ylide: a one-carbon homologative relay ring expansion.
2007 Feb 21
Total synthesis of azumamide A and azumamide E, evaluation as histone deacetylase inhibitors, and design of a more potent analogue.
2007 Mar 15
Beneficial effects of a diabetes specific formula on insulin sensitivity and free fatty acid in patients with type 2 diabetes mellitus.
2008 Apr 20
Impact of glycemic control on the incidence of acute kidney injury in critically ill patients: a comparison of two strategies using the RIFLE criteria.
2010 Jun

Sample Use Guides

Unknown
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:01:53 UTC 2023
Edited
by admin
on Fri Dec 15 15:01:53 UTC 2023
Record UNII
57OWB0Q221
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SULFOXONE SODIUM
MI   ORANGE BOOK  
Common Name English
DIASONE SODIUM
Brand Name English
ALDESULPHONE SODIUM
Common Name English
NSC-27222
Code English
SULFOXONE SODIUM [ORANGE BOOK]
Common Name English
ALDESULFONE SODIUM [MART.]
Common Name English
DISODIUM (SULFONYLBIS(P-PHENYLENEIMINO))DIMETHANESULFINATE
Common Name English
SULFOXONE SODIUM [MI]
Common Name English
Aldesulfone sodium [WHO-DD]
Common Name English
METHANESULFINIC ACID, (SULFONYLBIS(1,4-PHENYLENEIMINO))BIS-, DISODIUM SALT
Common Name English
ALDESULFONE SODIUM
INN   MART.   WHO-DD  
INN  
Official Name English
aldesulfone sodium [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29739
Created by admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
WHO-ATC J04BA03
Created by admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
Code System Code Type Description
WIKIPEDIA
ALDESULFONE SODIUM
Created by admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
PRIMARY
DRUG BANK
DB01145
Created by admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
PRIMARY
MERCK INDEX
m10368
Created by admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
PRIMARY Merck Index
SMS_ID
100000087868
Created by admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
PRIMARY
NSC
27222
Created by admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
PRIMARY
EVMPD
SUB05304MIG
Created by admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
PRIMARY
ChEMBL
CHEMBL1570
Created by admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
PRIMARY
PUBCHEM
8954
Created by admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
PRIMARY
INN
971
Created by admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
PRIMARY
MESH
C036115
Created by admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
PRIMARY
CAS
144-75-2
Created by admin on Fri Dec 15 15:01:53 UTC 2023 , Edited by admin on Fri Dec 15 15:01:53 UTC 2023
PRIMARY
NCI_THESAURUS
C66574
Created by admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
PRIMARY
EPA CompTox
DTXSID9023623
Created by admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
PRIMARY
FDA UNII
57OWB0Q221
Created by admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY